Astellas Pharma has filed a federal lawsuit accusing China’s Qilu Pharma of infringing on its patent protections for the blockbuster overactive bladder drug Myrbetriq (mirabegron) by preparing a generic version. Read More

Italian drugmaker Chiesi Farmaceutici plans to extend its rare disease portfolio in a $1.48 billion buyout of UK-based Amryt Pharma, gaining Amryt’s Filsuvez, a naturally derived product just approved in Europe for treating the rare inherited skin disorder epidermolysis bullosa. Read More

Eli Lilly and South San Francisco, Calif.-headquartered TRexBio have inked a multi-year research collaboration and licensing deal potentially worth up to $1.1 billion to develop therapies for immune-mediated diseases. Read More

AstraZeneca announced a plan to purchase Waltham, Mass.-based CinCor Pharma in a deal worth up to $1.8 billion as it looks to expand its pipeline of heart and kidney drugs with CinCor’s hypertension candidate baxdrostat. Read More

Dutch biotech Synaffix has signed a $2 billion licensing agreement with Amgen to bring a new generation of antibody-drug conjugates (ADC) to market. Read More